Program
vonicog alfa
Also written as “Vonicog Alfa”, “Vonicog alfa” and “VONVENDI”.
Its studies are mostly in von Willebrand Diseases, led by Takeda.
Furthest: phase 3, since Aug 4, 20116 company-led studies, 2 open or runningNext primary completion: Nov 25, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 62 open or running | phase 3since Aug 4, 2011 | Aug 4, 2011 | Nov 25, 2027phase 3 · NCT07129343 |
Also a collaborator on its studies: takeda-development-center-americas-inc and baxalta-innovations-gmbh-now-part-of-shire.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2011First study: phase 3 study in von Willebrand DiseasesFirst studyNCT01410227 · 49 enrolled · United States, Australia, Austria and more
- Oct 27, 2014Phase 3 study in von Willebrand DiseasesNCT02283268 · 24 enrolled · United States, Australia, Austria and more
- Oct 12, 2016Phase 3 study in von Willebrand DiseasesNCT02932618 · 47 enrolled · United States, Austria, Belgium and more
- Nov 22, 2016Phase 3 study in von Willebrand DiseasesNCT02973087 · 29 enrolled · United States, Canada, France and more
- Oct 14, 2022Phase 3 study in von Willebrand DiseasesNCT05582993 · 24 planned · United States, France, Ireland and more
- Aug 12, 2025Phase 3 study in von Willebrand DiseasesNCT07129343 · 20 planned · China
Ahead
- Nov 25, 2027Primary completion: phase 3 study in von Willebrand DiseasesNCT07129343
- Apr 11, 2030Primary completion: phase 3 study in von Willebrand DiseasesNCT05582993
TargetBeta
VWF →read by rule
“von Willebrand factor exogenous protein”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07129343von Willebrand Diseases · China | 3 | Recruiting | Nov 25, 2027 | 20 |
| NCT05582993von Willebrand Diseases · United States, France, Ireland and more | 3 | Recruiting | Apr 11, 2030 | 24 |
| NCT02973087von Willebrand Diseases · United States, Canada, France and more | 3 | Completed | Jul 6, 2020 | 29 |
| NCT02932618von Willebrand Diseases · United States, Austria, Belgium and more | 3 | Completed | Apr 17, 2026 | 47 |
| NCT02283268von Willebrand Diseases · United States, Australia, Austria and more | 3 | Completed | Jul 6, 2016 | 24 |
| NCT01410227von Willebrand Diseases · United States, Australia, Austria and more | 3 | Completed | Feb 1, 2014 | 49 |
How it is read
Names in the registry
- “Vonicog Alfa”, 1 entry
- “Vonicog alfa”, 1 entry
- “VONVENDI”, 1 entry
- “von Willebrand factor (Recombinant)”, 1 entry
- “Recombinant von Willebrand factor (rVWF)”, 1 entry
Conditions, from the studies’ own filings
- von Willebrand Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.